NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA,
Peptonic Medical AB (publ) (“Peptonic”) announces that the United States Patent and Trademark Office (“USPTO”) has granted patent (16238.0043U1) for the treatment and prevention of
Peptonic Medical AB (publ) (“Peptonic”) has signed an exclusive distribution agreement with FirstAid4All to launch Peptonic’s products in intimate self-care in Belgium, the Netherlands, and
Peptonic Medical AB (“Peptonic”) clarifies short term strategic priorities under the leadership of its new CEO. Committed to achieving tangible results, the company is prioritizing
Peptonic Medical AB (publ) today announced the launch of two new products on the home market in Sweden: VagiVital Menopause FSH Test and VagiVital Urinary
